Patrick D.  Spangler net worth and biography

Patrick Spangler Biography and Net Worth

Director of OptimizeRx
Patrick Spangler has over 32 years of experience in IPO’s, mergers and acquisitions, operations and financial management experience in the medical device and health care IT industries. As a transformational leader he has been responsible for driving high-performance emerging growth firms as well as large publicly traded companies and has also served in the private equity sector successfully improving operational results and exit strategies with a broad array of portfolio companies. He currently serves as Chief Financial Officer of On Target Laboratories which has developed fluorescent markers to target and illuminate cancer during surgery. Prior to On Target Laboratories, Pat served as Chief Financial Officer of MHC Software supplying document automation software to a variety of industries. Previous to MHC, Pat served as Chief Financial Officer of Vigilanz Corporation, Chief Financial Officer of Healthland Inc, SVP and CFO for Epocrates (EPOC), SVP and CFO of ev3 Inc. (EVVV), and ... Executive Vice President and Chief Financial Officer and Assistant Secretary for EMPI Inc (EMPI). Prior to joining EMPI Inc. Pat served for over eleven years in various senior finance leadership positions at Medtronic, Inc (MDT).  

Pat holds a Bachelor of Science in Accounting from the University of Minnesota, a Master of Business Taxation from the University of Minnesota and a Master of Business Administration from University of Chicago and also serves on the Board of Directors of Lifespace Communities Inc, OptimizeRx (OPRX) and previously served on the board of Urologix Inc (ULGX) a leader in less invasive in office BPH treatment.

How do I contact Patrick D. Spangler?

The corporate mailing address for Mr. Spangler and other OptimizeRx executives is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. OptimizeRx can also be reached via phone at (248) 651-6568 and via email at [email protected]. Learn More on Patrick D. Spangler's contact information.

Has Patrick D. Spangler been buying or selling shares of OptimizeRx?

Patrick D. Spangler has not been actively trading shares of OptimizeRx within the last three months. Most recently, Patrick D. Spangler sold 6,252 shares of the business's stock in a transaction on Thursday, November 11th. The shares were sold at an average price of $84.38, for a transaction totalling $527,543.76. Learn More on Patrick D. Spangler's trading history.

Who are OptimizeRx's active insiders?

OptimizeRx's insider roster includes Douglas Baker (CFO), William Febbo (CEO), Miriam Paramore (Insider), Stephen Silvestro (Insider), and Patrick Spangler (Director). Learn More on OptimizeRx's active insiders.

Are insiders buying or selling shares of OptimizeRx?

During the last twelve months, insiders at the sold shares 1 times. They sold a total of 4,000 shares worth more than $60,760.00. The most recent insider tranaction occured on January, 9th when General Counsel Marion Odence-Ford sold 4,000 shares worth more than $60,760.00. Insiders at OptimizeRx own 4.4% of the company. Learn More about insider trades at OptimizeRx.

Information on this page was last updated on 1/9/2024.

Patrick D. Spangler Insider Trading History at OptimizeRx

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/11/2021Sell6,252$84.38$527,543.76View SEC Filing Icon  
6/27/2018Buy95$9.95$945.25View SEC Filing Icon  
See Full Table

Patrick D. Spangler Buying and Selling Activity at OptimizeRx

This chart shows Patrick D Spangler's buying and selling at OptimizeRx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

OptimizeRx Company Overview

OptimizeRx logo
OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow. The company also offers Social Network Banner Messaging solution to deliver banner messaging to HCPs within their social network apps; Institutional Account-based Banner Messaging solution that provides its clients access to delivering banner messaging online and on the intranets of targeted health system accounts; and Financial Messaging solution, which provides prescribers visibility to branded copay offers and other patient support programs directly within their electronic health record and/or e-Prescribe systems. In addition, it provides Patient Engagement, a technology solution that provides digital messaging services through its cloud-based Mobile Health Messenger platform; HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance; and Therapy Initiation Workflow, a group of digital solutions that focuses on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was founded in 2006 and is headquartered in Rochester, Michigan.
Read More

Today's Range

Now: $12.30
Low: $11.65
High: $12.40

50 Day Range

MA: $14.62
Low: $11.47
High: $16.17

2 Week Range

Now: $12.30
Low: $6.92
High: $16.65

Volume

196,520 shs

Average Volume

117,898 shs

Market Capitalization

$223.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01